

Sheet No.

Box No. VIII(ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT

The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII(I) to (v) (in general and the specific Notes to Box No. VIII(ii)). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51*bis*. 1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

in relation to international application No. PCT/EP2004/010845

GLAXO GROUP LIMITED is entitled to apply for and be granted a patent by virtue of the following:

Contract of employment between inventors and GlaxoSmithKline Services Unlimited

Inventors:

JOHNSON, Christopher Norbert

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

MOSS, Stephen Frederick

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

WITTY, David R

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

And subsequent assignment from GlaxoSmithKline Services Unlimited to Glaxo Group Limited

This declaration is made for the purposes of all designations except the designation of the United States of America.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(ii)".

Sheet No.

Box No. VIII(iii) DECLARATION: ENTITLEMENT TO CLAIM PRIORITY

The declaration must conform to the standardized wording provided for in Section 213; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII(iii) and 51*bis*.1(a)(iii)

Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application specified below, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51*bis*.1(a)(iii)):

in relation to international application No. PCT/EP2004/010845

GLAXO GROUP LIMITED is entitled to claim priority of earlier application No. 0322510.9 filed in the United Kingdom by virtue of the following:

Inventors:

JOHNSON, Christopher Norbert

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

MOSS, Stephen Frederick

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

WITTY, David R

GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW
United Kingdom

And subsequent assignment from GlaxoSmithKline Services Unlimited to Glaxo Group Limited

This declaration is made for the purposes of all designations, except the designation of the United States of America.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iii)".

Form PCT/RO/101 (declaration sheet (iii)) (March 2001; reprint January 2003)

See Notes to the request form

Sheet No.

Box No. VIII(iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America). The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII(I) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))

for the purposes of the designation of the United States of America:

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. PCT/EP2004/010845 (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications:

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: Christopher Norbert JOHNSON

Residence: Harlow, Essex, United Kingdom
(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: GB

Inventor's Signature: Christopher Norbert Johnson
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 6th December 2004
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: Stephen Frederick MOSS

Residence: Harlow, Essex, United Kingdom
(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: GB

Inventor's Signature: Stephen Frederick Moss
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 3rd December 2004
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☒ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iv)".

Sheet No.

Continuation of Box No. VIII(i) to (v) Declaration

If the space is insufficient in any of Boxes Nos. VIII(I) to (v) to furnish all the informatino, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII " (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: David R WITTY

Residence: Harlow, Essex, United Kingdom
(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: GB

Inventor's Signature: Daniel R. Witty
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 3rd December 2004
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name:

Residence:
(city and either US state, if applicable, or country)

Mailing Address:

Citizenship:

Inventor's Signature: _____
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)